Free Trial

AxoGen (AXGN) Financials

AxoGen logo
$11.30 +0.23 (+2.08%)
Closing price 04:00 PM Eastern
Extended Trading
$11.56 +0.25 (+2.26%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for AxoGen

Annual Income Statements for AxoGen

This table shows AxoGen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-9.96 -22 -29
Consolidated Net Income / (Loss)
-9.96 -22 -29
Net Income / (Loss) Continuing Operations
-9.96 -22 -29
Total Pre-Tax Income
-9.96 -22 -29
Total Operating Income
-3.29 -21 -30
Total Gross Profit
142 122 109
Total Revenue
187 159 139
Operating Revenue
187 159 139
Total Cost of Revenue
45 37 30
Operating Cost of Revenue
45 37 30
Total Operating Expenses
145 143 139
Selling, General & Admin Expense
39 38 41
Marketing Expense
78 78 72
Research & Development Expense
28 27 26
Total Other Income / (Expense), net
-6.68 -0.25 0.76
Interest Expense
8.21 2.84 0.62
Interest & Investment Income
1.14 1.49 0.57
Other Income / (Expense), net
0.39 1.09 0.81
Basic Earnings per Share
($0.23) ($0.51) ($0.69)
Weighted Average Basic Shares Outstanding
44.26M 42.88M 42.08M
Diluted Earnings per Share
($0.23) ($0.51) ($0.69)
Weighted Average Diluted Shares Outstanding
44.26M 42.88M 42.08M
Weighted Average Basic & Diluted Shares Outstanding
44.34M 43.21M 42.60M

Quarterly Income Statements for AxoGen

This table shows AxoGen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
0.45 -1.86 -1.92 -6.64 -3.89 -4.09 -6.66 -7.07 -5.42 -4.32
Consolidated Net Income / (Loss)
0.45 -1.86 -1.92 -6.64 -3.89 -4.09 -6.66 -7.07 -5.42 -4.32
Net Income / (Loss) Continuing Operations
0.45 -1.86 -1.92 -6.64 -3.89 -4.09 -6.66 -7.07 -5.38 -4.32
Total Pre-Tax Income
0.45 -1.86 -1.92 -6.64 -3.89 -4.09 -6.66 -7.07 -5.38 -4.32
Total Operating Income
2.02 -0.32 -0.43 -4.56 -3.19 -4.03 -6.90 -7.34 -5.61 -4.86
Total Gross Profit
38 36 35 33 32 32 30 28 24 31
Total Revenue
49 49 48 41 43 41 38 37 36 37
Operating Revenue
49 49 48 41 43 41 38 37 36 37
Total Cost of Revenue
12 12 13 8.76 11 9.57 8.50 8.17 12 6.18
Operating Cost of Revenue
12 12 13 8.76 11 9.57 8.50 8.17 12 6.18
Total Operating Expenses
36 37 36 37 35 36 37 36 30 36
Selling, General & Admin Expense
8.83 11 9.42 9.96 7.93 9.87 11 10 13 8.80
Marketing Expense
20 19 20 20 20 19 19 19 12 20
Research & Development Expense
6.70 7.00 6.66 7.41 7.18 6.69 7.14 6.33 5.28 7.05
Total Other Income / (Expense), net
-1.57 -1.54 -1.49 -2.08 -0.70 -0.06 0.24 0.27 0.19 0.54
Interest Expense
1.80 1.89 2.19 2.33 1.84 0.83 0.15 0.02 -0.04 0.06
Interest & Investment Income
0.24 0.39 0.23 0.29 0.34 0.37 0.24 0.55 - 0.19
Weighted Average Basic Shares Outstanding
44.26M 43.88M 43.71M 43.23M 42.88M 43.02M 42.86M 42.57M 42.08M 42.22M
Weighted Average Diluted Shares Outstanding
44.26M 43.88M 43.71M 43.23M 42.88M 43.02M 42.86M 42.57M 42.08M 42.22M
Weighted Average Basic & Diluted Shares Outstanding
44.34M 44.01M 43.83M 43.70M 43.21M 43.04M 42.98M 42.83M 42.60M 42.29M

Annual Cash Flow Statements for AxoGen

This table details how cash moves in and out of AxoGen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-3.47 15 -17
Net Cash From Operating Activities
4.54 -5.72 -16
Net Cash From Continuing Operating Activities
4.54 -5.72 -16
Net Income / (Loss) Continuing Operations
-9.96 -22 -29
Consolidated Net Income / (Loss)
-9.96 -22 -29
Depreciation Expense
6.47 4.22 2.83
Amortization Expense
2.26 2.23 2.92
Non-Cash Adjustments To Reconcile Net Income
15 11 13
Changes in Operating Assets and Liabilities, net
-8.86 -1.16 -5.95
Net Cash From Investing Activities
-10 19 -3.20
Net Cash From Continuing Investing Activities
-10 19 -3.20
Purchase of Property, Plant & Equipment
-3.10 -14 -20
Acquisitions
-1.42 -1.05 -1.18
Purchase of Investments
-5.77 -10 -39
Sale and/or Maturity of Investments
0.00 44 57
Net Cash From Financing Activities
2.29 1.95 1.79
Net Cash From Continuing Financing Activities
2.29 1.95 1.79
Repayment of Debt
-0.01 -0.01 -0.01
Issuance of Common Equity
2.30 1.96 1.81
Cash Interest Paid
7.30 1.94 0.00

Quarterly Cash Flow Statements for AxoGen

This table details how cash moves in and out of AxoGen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
8.89 -0.53 3.48 -15 -0.07 7.63 16 -7.58 0.97 2.50
Net Cash From Operating Activities
8.74 3.90 4.17 -12 -0.21 1.63 0.29 -7.42 1.36 -0.69
Net Cash From Continuing Operating Activities
8.74 3.90 4.17 -12 -0.21 1.63 0.29 -7.42 1.36 -0.69
Net Income / (Loss) Continuing Operations
0.45 -1.86 -1.92 -6.64 -3.89 -4.09 -6.66 -7.07 -5.42 -4.32
Consolidated Net Income / (Loss)
0.45 -1.86 -1.92 -6.64 -3.89 -4.09 -6.66 -7.07 -5.42 -4.32
Depreciation Expense
1.64 1.65 1.66 1.52 1.56 1.15 0.80 0.71 0.65 0.76
Amortization Expense
0.50 0.54 0.63 0.60 0.52 0.48 0.47 0.75 0.75 0.74
Non-Cash Adjustments To Reconcile Net Income
3.14 2.11 5.28 4.11 0.26 2.69 5.28 2.49 2.14 3.28
Changes in Operating Assets and Liabilities, net
3.01 1.46 -1.48 -12 1.34 1.40 0.40 -4.30 3.25 -1.15
Net Cash From Investing Activities
-0.81 -5.00 -1.23 -3.25 -0.28 5.99 14 -0.79 -1.21 2.97
Net Cash From Continuing Investing Activities
-0.81 -5.00 -1.23 -3.25 -0.28 5.99 14 -0.79 -1.21 2.97
Purchase of Property, Plant & Equipment
-0.67 -0.60 -0.91 -0.92 -1.46 -3.69 -4.42 -4.30 -6.62 -4.37
Acquisitions
-0.14 -0.54 -0.32 -0.42 -0.31 -0.22 -0.26 -0.25 -0.15 -0.18
Net Cash From Financing Activities
0.97 0.57 0.54 0.20 0.42 0.01 0.90 0.63 0.81 0.22
Net Cash From Continuing Financing Activities
0.97 0.57 0.54 0.20 0.42 0.01 0.90 0.63 0.81 0.22
Repayment of Debt
-0.00 -0.00 -0.00 -0.00 -0.00 0.01 -0.01 -0.00 -0.00 -0.01
Issuance of Common Equity
0.97 0.57 0.55 0.21 0.42 - 0.91 0.63 0.82 0.22
Cash Interest Paid
1.57 1.98 2.10 1.66 1.62 0.33 - 0.00 - -

Annual Balance Sheets for AxoGen

This table presents AxoGen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
204 197 195
Total Current Assets
99 88 98
Cash & Equivalents
28 31 15
Restricted Cash
6.00 6.00 6.25
Short-Term Investments
5.93 0.00 34
Accounts Receivable
24 25 22
Inventories, net
33 23 19
Prepaid Expenses
2.45 2.81 1.94
Plant, Property, & Equipment, net
85 89 79
Total Noncurrent Assets
20 20 18
Intangible Assets
5.58 4.53 3.65
Other Noncurrent Operating Assets
14 16 14
Total Liabilities & Shareholders' Equity
204 197 195
Total Liabilities
100 101 94
Total Current Liabilities
31 30 24
Accounts Payable
29 29 22
Other Current Liabilities
1.97 1.55 1.31
Total Noncurrent Liabilities
69 71 71
Long-Term Debt
47 47 46
Capital Lease Obligations
19 21 20
Other Noncurrent Operating Liabilities
2.49 2.99 4.52
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
104 96 101
Total Preferred & Common Equity
104 96 101
Total Common Equity
104 96 101
Common Stock
395 377 361
Retained Earnings
-291 -281 -260

Quarterly Balance Sheets for AxoGen

This table presents AxoGen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
192 189 187 195 192 189 196
Total Current Assets
86 82 79 87 86 89 102
Cash & Equivalents
19 19 16 31 23 7.71 14
Restricted Cash
6.00 6.00 6.00 6.00 6.25 6.25 6.25
Short-Term Investments
5.87 1.94 1.92 1.49 11 30 39
Accounts Receivable
25 25 24 23 22 22 21
Inventories, net
29 28 28 23 21 20 19
Prepaid Expenses
1.73 1.96 3.18 2.57 2.58 2.45 2.61
Plant, Property, & Equipment, net
86 87 88 89 87 83 75
Total Noncurrent Assets
20 20 20 18 18 18 18
Intangible Assets
5.22 4.97 4.77 4.29 4.05 3.86 3.45
Other Noncurrent Operating Assets
15 15 15 14 14 14 15
Total Liabilities & Shareholders' Equity
192 189 187 195 192 189 196
Total Liabilities
93 93 93 97 94 92 94
Total Current Liabilities
23 23 23 27 24 21 24
Accounts Payable
21 22 21 26 23 20 22
Other Current Liabilities
1.86 1.75 1.64 1.10 1.04 1.05 1.53
Total Noncurrent Liabilities
70 70 70 70 71 71 71
Long-Term Debt
47 47 47 46 46 46 45
Capital Lease Obligations
20 20 21 - - - -
Other Noncurrent Operating Liabilities
2.54 2.55 2.92 24 24 25 25
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
99 96 93 98 97 98 101
Total Preferred & Common Equity
99 96 93 98 97 98 101
Total Common Equity
99 96 93 98 97 98 101
Common Stock
391 386 381 375 370 364 356
Retained Earnings
-292 -290 -288 -277 -273 -267 -254

Annual Metrics And Ratios for AxoGen

This table displays calculated financial ratios and metrics derived from AxoGen's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
17.81% 14.74% 8.81%
EBITDA Growth
141.88% 39.85% -14.88%
EBIT Growth
85.77% 29.51% -12.33%
NOPAT Growth
84.68% 27.75% -16.88%
Net Income Growth
54.12% 24.98% -7.27%
EPS Growth
54.90% 26.09% -6.15%
Operating Cash Flow Growth
179.34% 64.42% -19.85%
Free Cash Flow Firm Growth
75.93% 34.88% -11.53%
Invested Capital Growth
3.76% 12.77% 27.60%
Revenue Q/Q Growth
3.58% 4.44% 3.45%
EBITDA Q/Q Growth
326.24% 22.97% -2.90%
EBIT Q/Q Growth
60.29% 14.55% -1.70%
NOPAT Q/Q Growth
61.32% 10.11% -0.87%
Net Income Q/Q Growth
30.36% 6.55% -0.45%
EPS Q/Q Growth
25.81% 10.53% -1.47%
Operating Cash Flow Q/Q Growth
202.81% -37.97% 15.18%
Free Cash Flow Firm Q/Q Growth
80.52% 15.57% -0.71%
Invested Capital Q/Q Growth
-3.49% 19.68% 27.98%
Profitability Metrics
- - -
Gross Margin
75.79% 76.64% 78.51%
EBITDA Margin
3.11% -8.76% -16.70%
Operating Margin
-1.75% -13.50% -21.44%
EBIT Margin
-1.55% -12.81% -20.85%
Profit (Net Income) Margin
-5.32% -13.66% -20.89%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
343.70% 106.62% 100.19%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-1.79% -12.60% -20.80%
ROIC Less NNEP Spread (ROIC-NNEP)
-28.23% -44.63% 98.73%
Return on Net Nonoperating Assets (RNNOA)
-8.20% -9.48% -6.31%
Return on Equity (ROE)
-9.99% -22.08% -27.11%
Cash Return on Invested Capital (CROIC)
-5.48% -24.60% -45.06%
Operating Return on Assets (OROA)
-1.45% -10.39% -14.32%
Return on Assets (ROA)
-4.98% -11.07% -14.35%
Return on Common Equity (ROCE)
-9.99% -22.08% -27.11%
Return on Equity Simple (ROE_SIMPLE)
-9.59% -22.70% -28.66%
Net Operating Profit after Tax (NOPAT)
-2.30 -15 -21
NOPAT Margin
-1.23% -9.45% -15.01%
Net Nonoperating Expense Percent (NNEP)
26.45% 32.03% -119.54%
Return On Investment Capital (ROIC_SIMPLE)
-1.35% -9.19% -12.44%
Cost of Revenue to Revenue
24.21% 23.36% 21.49%
SG&A Expenses to Revenue
20.84% 24.16% 29.52%
R&D to Revenue
14.82% 17.19% 18.49%
Operating Expenses to Revenue
77.54% 90.14% 99.95%
Earnings before Interest and Taxes (EBIT)
-2.90 -20 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
5.83 -14 -23
Valuation Ratios
- - -
Price to Book Value (P/BV)
6.98 3.07 4.18
Price to Tangible Book Value (P/TBV)
7.38 3.23 4.34
Price to Revenue (P/Rev)
3.87 1.85 3.05
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
5.74 2.57 3.86
Enterprise Value to Revenue (EV/Rev)
4.02 2.04 3.13
Enterprise Value to EBITDA (EV/EBITDA)
129.05 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
165.93 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.64 0.71 0.65
Long-Term Debt to Equity
0.64 0.71 0.65
Financial Leverage
0.29 0.21 -0.06
Leverage Ratio
2.01 1.99 1.89
Compound Leverage Factor
6.90 2.13 1.89
Debt to Total Capital
39.10% 41.46% 39.56%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
39.10% 41.46% 39.56%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
60.90% 58.54% 60.44%
Debt to EBITDA
11.44 -4.87 -2.86
Net Debt to EBITDA
4.67 -2.21 -0.48
Long-Term Debt to EBITDA
11.44 -4.87 -2.86
Debt to NOPAT
-29.00 -4.51 -3.18
Net Debt to NOPAT
-11.84 -2.04 -0.53
Long-Term Debt to NOPAT
-29.00 -4.51 -3.18
Altman Z-Score
3.63 0.56 1.50
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
3.24 2.89 4.13
Quick Ratio
1.88 1.85 2.99
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-7.06 -29 -45
Operating Cash Flow to CapEx
146.24% -41.21% -80.02%
Free Cash Flow to Firm to Interest Expense
-0.86 -10.35 -72.18
Operating Cash Flow to Interest Expense
0.55 -2.02 -25.75
Operating Cash Flow Less CapEx to Interest Expense
0.17 -6.91 -57.92
Efficiency Ratios
- - -
Asset Turnover
0.94 0.81 0.69
Accounts Receivable Turnover
7.61 6.72 6.87
Inventory Turnover
1.61 1.77 1.67
Fixed Asset Turnover
2.16 1.89 1.95
Accounts Payable Turnover
1.58 1.45 1.33
Days Sales Outstanding (DSO)
47.98 54.32 53.13
Days Inventory Outstanding (DIO)
226.12 206.00 218.19
Days Payable Outstanding (DPO)
231.44 252.19 275.22
Cash Conversion Cycle (CCC)
42.67 8.13 -3.90
Capital & Investment Metrics
- - -
Invested Capital
131 126 112
Invested Capital Turnover
1.45 1.33 1.39
Increase / (Decrease) in Invested Capital
4.76 14 24
Enterprise Value (EV)
752 325 433
Market Capitalization
725 294 422
Book Value per Share
$2.36 $2.22 $2.39
Tangible Book Value per Share
$2.23 $2.12 $2.30
Total Capital
171 163 167
Total Debt
67 68 66
Total Long-Term Debt
67 68 66
Net Debt
27 31 11
Capital Expenditures (CapEx)
3.10 14 20
Debt-free, Cash-free Net Working Capital (DFCFNWC)
29 21 19
Debt-free Net Working Capital (DFNWC)
69 58 74
Net Working Capital (NWC)
69 58 74
Net Nonoperating Expense (NNE)
7.66 6.69 8.15
Net Nonoperating Obligations (NNO)
27 31 11
Total Depreciation and Amortization (D&A)
8.73 6.44 5.74
Debt-free, Cash-free Net Working Capital to Revenue
15.55% 12.92% 13.91%
Debt-free Net Working Capital to Revenue
36.62% 36.21% 53.63%
Net Working Capital to Revenue
36.62% 36.21% 53.63%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($0.23) ($0.51) ($0.69)
Adjusted Weighted Average Basic Shares Outstanding
44.26M 42.88M 42.08M
Adjusted Diluted Earnings per Share
($0.23) ($0.51) ($0.69)
Adjusted Weighted Average Diluted Shares Outstanding
44.26M 42.88M 42.08M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
44.34M 43.21M 42.60M
Normalized Net Operating Profit after Tax (NOPAT)
-2.30 -15 -21
Normalized NOPAT Margin
-1.23% -9.45% -15.01%
Pre Tax Income Margin
-5.32% -13.66% -20.89%
Debt Service Ratios
- - -
EBIT to Interest Expense
-0.35 -7.18 -46.30
NOPAT to Interest Expense
-0.28 -5.30 -33.33
EBIT Less CapEx to Interest Expense
-0.73 -12.08 -78.48
NOPAT Less CapEx to Interest Expense
-0.66 -10.19 -65.50
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AxoGen

This table displays calculated financial ratios and metrics derived from AxoGen's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
15.10% 17.86% 25.57% 12.86% 18.69% 11.67% 10.74% 18.24% 14.67% 18.44%
EBITDA Growth
1,453.75% 192.09% 142.35% 59.59% 93.11% 32.17% 10.11% 36.36% -17.13% 45.68%
EBIT Growth
184.57% 90.33% 100.55% 39.50% 59.24% 18.32% 10.32% 31.31% -9.00% 34.09%
NOPAT Growth
190.21% 92.15% 93.80% 37.88% 43.05% 17.10% 12.90% 35.15% -4.76% 27.42%
Net Income Growth
111.56% 54.56% 71.16% 6.21% 28.11% 5.30% 13.95% 38.35% -2.44% 39.53%
EPS Growth
0.00% 60.00% 75.00% 11.76% 42.86% 0.00% 11.11% 37.04% -7.69% 41.18%
Operating Cash Flow Growth
4,239.81% 139.91% 1,326.37% -65.24% -115.49% 335.99% 105.13% 32.83% 189.96% -83.24%
Free Cash Flow Firm Growth
83.43% -46.35% -36.15% -39.86% 41.27% 24.21% -164.32% -274.40% -6.96% -22,885.83%
Invested Capital Growth
3.76% 28.68% 32.49% 37.96% 12.77% 20.59% 24.01% 32.04% 27.60% 37.98%
Revenue Q/Q Growth
1.56% 1.53% 15.79% -3.60% 4.00% 8.17% 4.07% 1.38% -2.15% 7.27%
EBITDA Q/Q Growth
125.99% -20.70% 193.40% -708.79% 84.63% 63.53% 10.87% -37.82% -51.43% 51.67%
EBIT Q/Q Growth
674.64% -1,048.65% 100.80% -92.96% 34.28% 46.21% 11.31% -29.99% -31.71% 40.94%
NOPAT Q/Q Growth
1,011.84% 26.17% 90.61% -42.77% 20.65% 41.68% 5.98% -30.90% -15.51% 38.73%
Net Income Q/Q Growth
124.22% 3.28% 71.05% -70.43% 4.79% 38.60% 5.85% -30.64% -25.41% 44.21%
EPS Q/Q Growth
0.00% 0.00% 73.33% -87.50% 20.00% 37.50% 5.88% -21.43% -40.00% 44.44%
Operating Cash Flow Q/Q Growth
123.92% -6.34% 133.96% -5,713.27% -112.98% 456.85% 103.93% -645.01% 297.68% 87.89%
Free Cash Flow Firm Q/Q Growth
91.01% 9.23% 17.82% -147.19% 20.63% 15.56% 15.58% -3.80% -2.43% -194.50%
Invested Capital Q/Q Growth
-3.49% 0.04% -0.87% 8.42% 19.68% 3.00% 3.22% -11.38% 27.98% 5.93%
Profitability Metrics
- - - - - - - - - -
Gross Margin
76.05% 74.91% 73.77% 78.83% 74.60% 76.82% 77.71% 77.71% 67.46% 83.29%
EBITDA Margin
8.41% 3.78% 4.84% -6.00% -0.72% -4.84% -14.35% -16.76% -12.33% -7.97%
Operating Margin
4.08% -0.65% -0.89% -11.02% -7.44% -9.75% -18.09% -20.02% -15.51% -13.14%
EBIT Margin
4.08% -0.72% 0.08% -11.12% -5.56% -8.79% -17.68% -20.75% -16.18% -12.02%
Profit (Net Income) Margin
0.91% -3.82% -4.01% -16.04% -9.07% -9.91% -17.46% -19.29% -14.97% -11.68%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.59% 100.00%
Interest Burden Percent
22.31% 529.34% -5,191.89% 144.18% 163.23% 112.68% 98.71% 92.99% 91.99% 97.19%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
5.94% -0.68% -0.91% -10.69% -6.95% -10.76% -20.23% -23.16% -15.05% -16.31%
ROIC Less NNEP Spread (ROIC-NNEP)
0.53% -8.08% -8.03% -25.76% -14.88% 31.02% 6.56% -8.73% 6.79% -13.51%
Return on Net Nonoperating Assets (RNNOA)
0.15% -1.81% -1.90% -6.17% -3.16% -0.95% -0.45% 1.16% -0.43% 4.10%
Return on Equity (ROE)
6.09% -2.49% -2.81% -16.86% -10.11% -11.71% -20.68% -22.00% -15.48% -12.22%
Cash Return on Invested Capital (CROIC)
-5.48% -30.01% -35.12% -42.97% -24.60% -35.97% -40.12% -48.25% -45.06% -59.22%
Operating Return on Assets (OROA)
3.82% -0.68% 0.07% -9.69% -4.51% -6.86% -13.49% -15.45% -11.12% -7.94%
Return on Assets (ROA)
0.85% -3.57% -3.66% -13.97% -7.35% -7.73% -13.32% -14.36% -10.29% -7.72%
Return on Common Equity (ROCE)
6.09% -2.49% -2.81% -16.86% -10.11% -11.71% -20.68% -22.00% -15.48% -12.22%
Return on Equity Simple (ROE_SIMPLE)
0.00% -14.39% -17.28% -22.84% 0.00% -23.76% -24.15% -25.17% 0.00% -28.41%
Net Operating Profit after Tax (NOPAT)
2.02 -0.22 -0.30 -3.19 -2.24 -2.82 -4.83 -5.14 -3.93 -3.40
NOPAT Margin
4.08% -0.45% -0.63% -7.71% -5.21% -6.83% -12.66% -14.02% -10.86% -9.20%
Net Nonoperating Expense Percent (NNEP)
5.41% 7.40% 7.12% 15.07% 7.93% -41.78% -26.79% -14.43% -21.84% -2.80%
Return On Investment Capital (ROIC_SIMPLE)
1.18% - - - -1.37% - - - -2.35% -
Cost of Revenue to Revenue
23.95% 25.09% 26.23% 21.17% 25.40% 23.18% 22.29% 22.29% 32.54% 16.71%
SG&A Expenses to Revenue
17.87% 22.27% 19.65% 24.06% 18.48% 23.92% 27.65% 27.44% 36.19% 23.80%
R&D to Revenue
13.57% 14.38% 13.90% 17.91% 16.72% 16.22% 18.72% 17.25% 14.60% 19.08%
Operating Expenses to Revenue
71.97% 75.56% 74.66% 89.85% 82.04% 86.57% 95.80% 97.73% 82.96% 96.43%
Earnings before Interest and Taxes (EBIT)
2.02 -0.35 0.04 -4.60 -2.39 -3.63 -6.75 -7.61 -5.85 -4.44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4.16 1.84 2.32 -2.48 -0.31 -2.00 -5.48 -6.14 -4.46 -2.94
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
6.98 6.18 3.31 3.74 3.07 2.20 4.03 4.13 4.18 4.97
Price to Tangible Book Value (P/TBV)
7.38 6.52 3.49 3.94 3.23 2.30 4.20 4.30 4.34 5.14
Price to Revenue (P/Rev)
3.87 3.40 1.82 2.13 1.85 1.41 2.64 2.79 3.05 3.76
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
5.74 4.79 2.63 2.86 2.57 2.11 3.87 4.07 3.86 5.60
Enterprise Value to Revenue (EV/Rev)
4.02 3.60 2.06 2.40 2.04 1.46 2.68 2.80 3.13 3.66
Enterprise Value to EBITDA (EV/EBITDA)
129.05 475.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
165.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.64 0.67 0.70 0.72 0.71 0.47 0.48 0.47 0.65 0.45
Long-Term Debt to Equity
0.64 0.67 0.70 0.72 0.71 0.47 0.48 0.47 0.65 0.45
Financial Leverage
0.29 0.22 0.24 0.24 0.21 -0.03 -0.07 -0.13 -0.06 -0.30
Leverage Ratio
2.01 1.96 1.97 1.97 1.99 1.96 1.95 1.92 1.89 1.87
Compound Leverage Factor
0.45 10.38 -102.46 2.84 3.26 2.21 1.92 1.79 1.74 1.82
Debt to Total Capital
39.10% 40.26% 41.28% 42.02% 41.46% 32.17% 32.21% 32.02% 39.56% 30.96%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
39.10% 40.26% 41.28% 42.02% 41.46% 32.17% 32.21% 32.02% 39.56% 30.96%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
60.90% 59.74% 58.72% 57.98% 58.54% 67.84% 67.79% 67.98% 60.44% 69.04%
Debt to EBITDA
11.44 48.98 -27.26 -6.58 -4.87 -2.57 -2.43 -2.34 -2.86 -2.02
Net Debt to EBITDA
4.67 26.66 -16.27 -4.27 -2.21 -0.43 -0.28 -0.09 -0.48 0.62
Long-Term Debt to EBITDA
11.44 48.98 -27.26 -6.58 -4.87 -2.57 -2.43 -2.34 -2.86 -2.02
Debt to NOPAT
-29.00 -11.26 -7.87 -5.16 -4.51 -2.77 -2.67 -2.55 -3.18 -2.21
Net Debt to NOPAT
-11.84 -6.13 -4.70 -3.36 -2.04 -0.47 -0.31 -0.10 -0.53 0.67
Long-Term Debt to NOPAT
-29.00 -11.26 -7.87 -5.16 -4.51 -2.77 -2.67 -2.55 -3.18 -2.21
Altman Z-Score
3.71 3.19 1.18 1.23 0.86 0.43 1.53 1.71 1.89 2.49
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
3.24 3.74 3.51 3.43 2.89 3.28 3.60 4.18 4.13 4.35
Quick Ratio
1.88 2.13 1.98 1.82 1.85 2.10 2.34 2.83 2.99 3.16
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.74 -31 -34 -41 -17 -21 -25 -29 -28 -28
Operating Cash Flow to CapEx
1,303.73% 653.43% 457.69% -1,327.49% -14.42% 44.07% 6.61% -172.47% 20.57% -15.77%
Free Cash Flow to Firm to Interest Expense
-1.52 -16.12 -15.38 -17.58 -8.97 -25.21 -166.79 -1,827.54 0.00 -450.86
Operating Cash Flow to Interest Expense
4.85 2.06 1.91 -5.27 -0.11 1.97 1.97 -463.94 0.00 -11.30
Operating Cash Flow Less CapEx to Interest Expense
4.48 1.75 1.49 -5.67 -0.91 -2.50 -27.86 -732.94 0.00 -82.93
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.94 0.94 0.91 0.87 0.81 0.78 0.76 0.74 0.69 0.66
Accounts Receivable Turnover
7.61 7.55 7.43 7.04 6.72 6.82 7.05 7.06 6.87 6.71
Inventory Turnover
1.61 1.47 1.45 1.34 1.77 1.54 1.43 1.44 1.67 1.36
Fixed Asset Turnover
2.16 2.07 1.99 1.92 1.89 1.86 1.87 1.92 1.95 2.04
Accounts Payable Turnover
1.58 1.64 1.61 1.53 1.45 1.36 1.30 1.30 1.33 1.07
Days Sales Outstanding (DSO)
47.98 48.33 49.15 51.82 54.32 53.49 51.74 51.71 53.13 54.40
Days Inventory Outstanding (DIO)
226.12 248.78 251.16 273.17 206.00 237.46 254.68 253.91 218.19 269.22
Days Payable Outstanding (DPO)
231.44 221.92 227.22 238.60 252.19 268.07 281.57 279.89 275.22 340.34
Cash Conversion Cycle (CCC)
42.67 75.18 73.10 86.39 8.13 22.88 24.85 25.73 -3.90 -16.73
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
131 136 136 137 126 106 103 99 112 88
Invested Capital Turnover
1.45 1.50 1.46 1.39 1.33 1.58 1.60 1.65 1.39 1.77
Increase / (Decrease) in Invested Capital
4.76 30 33 38 14 18 20 24 24 24
Enterprise Value (EV)
752 651 357 393 325 223 396 404 433 490
Market Capitalization
725 614 316 349 294 215 391 403 422 504
Book Value per Share
$2.36 $2.27 $2.19 $2.16 $2.22 $2.28 $2.27 $2.29 $2.39 $2.40
Tangible Book Value per Share
$2.23 $2.15 $2.08 $2.05 $2.12 $2.18 $2.17 $2.20 $2.30 $2.32
Total Capital
171 166 163 161 163 144 143 143 167 147
Total Debt
67 67 67 68 68 46 46 46 66 45
Total Long-Term Debt
67 67 67 68 68 46 46 46 66 45
Net Debt
27 36 40 44 31 7.79 5.37 1.81 11 -14
Capital Expenditures (CapEx)
0.67 0.60 0.91 0.92 1.46 3.69 4.42 4.30 6.62 4.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)
29 33 32 32 21 22 21 23 19 20
Debt-free Net Working Capital (DFNWC)
69 63 59 56 58 61 62 67 74 79
Net Working Capital (NWC)
69 63 59 56 58 61 62 67 74 79
Net Nonoperating Expense (NNE)
1.57 1.64 1.62 3.44 1.66 1.27 1.83 1.94 1.49 0.92
Net Nonoperating Obligations (NNO)
27 36 40 44 31 7.79 5.37 1.81 11 -14
Total Depreciation and Amortization (D&A)
2.14 2.19 2.28 2.12 2.08 1.63 1.27 1.46 1.39 1.50
Debt-free, Cash-free Net Working Capital to Revenue
15.55% 18.07% 18.28% 19.60% 12.92% 14.58% 14.51% 16.18% 13.91% 14.59%
Debt-free Net Working Capital to Revenue
36.62% 34.96% 33.92% 34.04% 36.21% 39.93% 42.07% 46.77% 53.63% 58.90%
Net Working Capital to Revenue
36.62% 34.96% 33.92% 34.04% 36.21% 39.93% 42.07% 46.77% 53.63% 58.90%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.04) ($0.04) ($0.15) ($0.08) ($0.10) ($0.16) ($0.17) ($0.14) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding
44.26M 43.88M 43.71M 43.23M 42.88M 43.02M 42.86M 42.57M 42.08M 42.22M
Adjusted Diluted Earnings per Share
$0.00 ($0.04) ($0.04) ($0.15) ($0.08) ($0.10) ($0.16) ($0.17) ($0.14) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding
44.26M 43.88M 43.71M 43.23M 42.88M 43.02M 42.86M 42.57M 42.08M 42.22M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
44.34M 44.01M 43.83M 43.70M 43.21M 43.04M 42.98M 42.83M 42.60M 42.29M
Normalized Net Operating Profit after Tax (NOPAT)
1.41 -0.22 -0.30 -3.19 -2.24 -2.82 -4.83 -5.14 -3.93 -3.40
Normalized NOPAT Margin
2.86% -0.45% -0.63% -7.71% -5.21% -6.83% -12.66% -14.02% -10.86% -9.20%
Pre Tax Income Margin
0.91% -3.82% -4.01% -16.04% -9.07% -9.91% -17.46% -19.29% -14.89% -11.68%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
1.12 -0.19 0.02 -1.98 -1.29 -4.39 -45.59 -475.44 0.00 -72.84
NOPAT to Interest Expense
1.12 -0.12 -0.14 -1.37 -1.21 -3.41 -32.64 -321.17 0.00 -55.71
EBIT Less CapEx to Interest Expense
0.75 -0.50 -0.40 -2.38 -2.09 -8.85 -75.42 -744.44 0.00 -144.48
NOPAT Less CapEx to Interest Expense
0.75 -0.43 -0.55 -1.77 -2.01 -7.87 -62.48 -590.17 0.00 -127.35
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About AxoGen's Financials

When does AxoGen's financial year end?

According to the most recent income statement we have on file, AxoGen's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AxoGen's net income changed over the last 2 years?

AxoGen's net income appears to be on a downward trend, with a most recent value of -$9.96 million in 2024, falling from -$28.95 million in 2022. The previous period was -$21.72 million in 2023. Check out AxoGen's forecast to explore projected trends and price targets.

What is AxoGen's operating income?
AxoGen's total operating income in 2024 was -$3.29 million, based on the following breakdown:
  • Total Gross Profit: $141.98 million
  • Total Operating Expenses: $145.26 million
How has AxoGen revenue changed over the last 2 years?

Over the last 2 years, AxoGen's total revenue changed from $138.58 million in 2022 to $187.34 million in 2024, a change of 35.2%.

How much debt does AxoGen have?

AxoGen's total liabilities were at $99.82 million at the end of 2024, a 1.3% decrease from 2023, and a 5.8% increase since 2022.

How much cash does AxoGen have?

In the past 2 years, AxoGen's cash and equivalents has ranged from $15.28 million in 2022 to $31.02 million in 2023, and is currently $27.55 million as of their latest financial filing in 2024.

How has AxoGen's book value per share changed over the last 2 years?

Over the last 2 years, AxoGen's book value per share changed from 2.39 in 2022 to 2.36 in 2024, a change of -1.1%.



This page (NASDAQ:AXGN) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners